Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Cancer
|
April 1, 2021
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis
Jessica N McAlpine, Derek S Chiu, Remi A Nout, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2023
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Karolin Heinze, Evan S Cairns, Shelby Thornton, et al.
EMBO Molecular Medicine
|
March 12, 2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, et al.
Nature Communications
|
February 18, 2017
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
Hong Xu, Marco Di Antonio, Steven McKinney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2020
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma
Pauline Krämer, Aline Talhouk, Mary Anne Brett, et al.
Gynecologic Oncology
|
November 11, 2022
Profiling the immune landscape in mucinous ovarian carcinoma
Nicola S Meagher, Phineas Hamilton, Katy Milne, et al.
Nature Medicine
|
February 26, 2020
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
Daisuke Ennishi, Shannon Healy, Ali Bashashati, et al.
The Journal of Pathology
|
December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
Virchows Archiv : an International Journal of Pathology
|
November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Eun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Cancer
|
April 1, 2021
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis
Jessica N McAlpine, Derek S Chiu, Remi A Nout, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2023
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Karolin Heinze, Evan S Cairns, Shelby Thornton, et al.
EMBO Molecular Medicine
|
March 12, 2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, et al.
Nature Communications
|
February 18, 2017
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
Hong Xu, Marco Di Antonio, Steven McKinney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2020
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma
Pauline Krämer, Aline Talhouk, Mary Anne Brett, et al.
Gynecologic Oncology
|
November 11, 2022
Profiling the immune landscape in mucinous ovarian carcinoma
Nicola S Meagher, Phineas Hamilton, Katy Milne, et al.
Nature Medicine
|
February 26, 2020
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
Daisuke Ennishi, Shannon Healy, Ali Bashashati, et al.
The Journal of Pathology
|
December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
Virchows Archiv : an International Journal of Pathology
|
November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Eun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Page
of 3